

**Minutes:** Confirmed

**Guideline Development Group Meeting 2: Cirrhosis**

**Date and Time:** 4<sup>th</sup> September 2014, 10am-4pm

**Place:** Royal College of Physicians, 11 St. Andrews Place, London

**Present:**

Iain Brew	General Practitioner, Leeds Community Healthcare NHS Trust
Andrew Fowell	Consultant Gastroenterologist & Hepatologist, Queen Alexandra Hospital, Portsmouth
Lynda Greenslade	Clinical Nurse Specialist in Hepatology, Royal Free London NHS Foundation Trust
Phillip Harrison	GDG Chair, Senior Lecturer & Consultant Hepatologist, King's College London
Brian Hogan	ST5 in Intensive Care Medicine, Homerton University Hospital (Specialist Trainee Adviser)
Mark Hudson	Consultant Hepatologist & Gastroenterologist, Newcastle Hospitals NHS Trust
Susan McRae	Patient/carer representative
Marsha Morgan	Principle Research Fellow & Honorary Consultant Physician, UCL Institute for Liver & Digestive Health
Valerie Ross	Lead Pharmacist in Hepatology, Barts Health NHS Trust
Andrew Langford	Patient/carer representative

**NCGC technical team**

Brian Hogan	ST5 in Intensive Care Medicine, Homerton University Hospital (Specialist Trainee Adviser)
Emily Davies	Senior Research Fellow
Martin Harker	Senior Health Economist
Katie Jones	Senior Project Manager
Jill Parnham	Operations Director
Heather Stegenga	Research Fellow
Lefteris Floris	Health Economist
Jill Cobb	Information scientist (AM only)

**In attendance:**

Caroline Keir	Guideline commissioning manager, NICE	AM only
---------------	---------------------------------------	---------

**Observers:**

Josh Reugger	Research Fellow	
--------------	-----------------	--

## Apologies

Gerri Mortimore                      Lead clinical nurse specialist, liver.

1. PH welcomed the group to the second meeting of the Cirrhosis GDG. Apologies were received from GM (Cirrhosis GDG). The GDG declared the following declarations of interest:

Name	DOI	Chair's action
PH, CK, MM,KJ, HS, JP, ED, SMR, BH, MH.	No new declarations	Nil
AL:	Declared a non-personal, non-specific, non-pecuniary interest: His name will be in a press release regarding the NICE decision on rifraximin for hepatic encephalopathy.	Declare and participate
LG:	Declared that Janssen have paid for attendance at Basel Liver meeting (normal, reasonable travel expenses).	Declare and participate
AF:	Declared a personal pecuniary interest: Conference attendance travel expenses only from Janssen in last 12 months.  Declared a non-personal pecuniary interest: Secretary for Wessex Gut Club. Organises twice annual meeting and arrangements for this is from up to 8 – 9 pharmaceutical companies. No money is received personally by AF and all monies are paid to the Gut Club.	Declare and participate
IB:	Declared a personal pecuniary interest: Received payment for chairing meetings and attending advisory boards from Janssen and Abvie.	No conflict of interest for the questions addressed at GDG2. Declare and participate.

2. ED presented to the group on the draft review questions.
3. ED presented to the group on the draft protocols relating to imaging, fibrosis tests and the use of individual tests.
4. HS presented to the group on the most clinically and cost effective antibiotic for the primary prevention of spontaneous bacterial peritonitis in patients with ascites due to cirrhosis, MHk presented to the group the economic evidence relating to the question. The GDG considered the evidence and drafted recommendations.

5. ED presented to the group on the most clinically and cost effective prophylactic antibiotic for the primary prevention of SBP in patients with cirrhosis, ascites and variceal bleeding.
6. MHk presented to the group on prioritisation of areas for original health economics analysis. PH thanked MHk for his presentation.
7. There was no other business.

**Date, time and venue of the next meeting**

**Friday 17<sup>th</sup> October 2014, 10am – 4pm, Boardroom, National Clinical Guideline Centre, 180 Great Portland Street.**